[HTML][HTML] Engineering CAR-T cells for next-generation cancer therapy
T cells engineered to express chimeric antigen receptors (CARs) with tumor specificity have
shown remarkable success in treating patients with hematologic malignancies and …
shown remarkable success in treating patients with hematologic malignancies and …
Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients
Acute myeloid leukemia (AML) is a serious, life-threatening, and hardly curable
hematological malignancy that affects the myeloid cell progenies and challenges patients of …
hematological malignancy that affects the myeloid cell progenies and challenges patients of …
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Despite impressive progress, more than 50% of patients treated with CD19-targeting
chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 …
chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 …
Mechanisms of resistance to CAR T cell therapy
NN Shah, TJ Fry - Nature reviews Clinical oncology, 2019 - nature.com
The successes with chimeric antigen receptor (CAR) T cell therapy in early clinical trials
involving patients with pre-B cell acute lymphoblastic leukaemia (ALL) or B cell lymphomas …
involving patients with pre-B cell acute lymphoblastic leukaemia (ALL) or B cell lymphomas …
Clinical lessons learned from the first leg of the CAR T cell journey
RG Majzner, CL Mackall - Nature medicine, 2019 - nature.com
Chimeric antigen receptor (CAR) T cell therapy for B cell malignancies has surpassed
expectations, driving an ever-expanding number of clinical trials and the first US Food and …
expectations, driving an ever-expanding number of clinical trials and the first US Food and …
Tumor antigen escape from CAR T-cell therapy
RG Majzner, CL Mackall - Cancer discovery, 2018 - AACR
Emerging data from chimeric antigen receptor (CAR) T-cell trials in B-cell malignancies
demonstrate that a common mechanism of resistance to this novel class of therapeutics is …
demonstrate that a common mechanism of resistance to this novel class of therapeutics is …
CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial
NN Shah, SL Highfill, H Shalabi, B Yates… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Patients with B-cell acute lymphoblastic leukemia who experience relapse after
or are resistant to CD19-targeted immunotherapies have limited treatment options. Targeting …
or are resistant to CD19-targeted immunotherapies have limited treatment options. Targeting …
A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity
M Boulch, M Cazaux, Y Loe-Mie, R Thibaut… - Science …, 2021 - science.org
Chimeric antigen receptor (CAR) T cell therapy relies on the activity of a large pool of tumor-
targeting cytotoxic effectors. Whether CAR T cells act autonomously or require interactions …
targeting cytotoxic effectors. Whether CAR T cells act autonomously or require interactions …
Born to survive: how cancer cells resist CAR T cell therapy
Although chimeric antigen receptor T cells demonstrated remarkable efficacy in patients with
chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This …
chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This …
Emerging cellular therapies for cancer
Genetically engineered T cells are powerful new medicines, offering hope for curative
responses in patients with cancer. Chimeric antigen receptor (CAR) T cells were recently …
responses in patients with cancer. Chimeric antigen receptor (CAR) T cells were recently …